

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 11/11/1967
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Epithelial Basement Membrane Zone Antibody IgA

ARUP test code 0092057

Epithelial BMZ Ab, IgA

See Note

IMMUNODERMATOLOGY REPORT

Specimen(s):
1. Serum specimen

Clinical/Diagnostic Information:
No clinical information provided.

DIAGNOSTIC INTERPRETATION

Negative IgA basement membrane zone antibodies

(See Results, Comments with additional test recommendations, separate concurrent IgG Epithelial Basement Membrane Zone Antibodies report with negative findings and additional comments, and Concurrent Test Results Summary Chart)

RESULTS

Indirect Immunofluorescence

Basement Membrane Zone IgA Antibodies

IgA: Negative, monkey esophagus substrate
Negative, human split skin substrate

Reference Range:
Positive (H) - Titer greater than 1:10
Borderline - Titer 1:10
Negative - Titer less than 1:10

IgA epidermal, epidermal-dermal combined, or,
dermal basement membrane zone antibody pattern =
linear IgA bullous dermatosis

(H = high/positive)

COMMENTS

Specific

These negative findings for IgA basement membrane zone antibodies by indirect immunofluorescence do not provide support for, but do not rule out, the diagnosis of linear IgA bullous dermatosis. These results do not rule out other immunobullous diseases.

To further evaluate for immunobullous disease, recommend serum testing for Bullous Pemphigoid (180 and 230) Antigens Antibodies IgG (ARUP test number 0092566), Collagen Type VII Antibody IgG (ARUP test number 2010905), and/or Pemphigus Panel (ARUP test number 0090650), which may be performed on this specimen by add-on test request through ARUP Client Services, 1-800-242-2787

H – high L – low * – abnormal C – critical

option 2.

See concurrent IgG Epithelial Basement Membrane Zone Antibodies test results with negative findings (separate report with additional comments), and see chart (below) for summary of concurrent test results.

CONCURRENT TEST RESULTS COMPARISON CHART

Basement Membrane Zone Antibodies

Serum Date of IgG and IgG4 IgA BP BP Coll
Number Specimen BMZ Titers BMZ Titers 180 230 VII

17-1898 05/08/17 IgG ME: Neg ME: NA NA NA NA
IgG SS: Neg SS: NA
IgG4 ME: Neg
IgG4 SS: Neg

17-1899 05/08/17 IgG ME: NA ME: Neg NA NA NA
IgG SS: NA SS: Neg
IgG4 ME: NA
IgG4 SS: NA

Chart Key:

IgG BMZ = IgG basement membrane zone (BMZ) antibodies by indirect immunofluorescence

IgG4 BMZ = IgG4 basement membrane zone (BMZ) antibodies by indirect immunofluorescence

IgA BMZ = IgA basement membrane zone (BMZ) antibodies by indirect immunofluorescence

ME = Antibody absence (negative) or presence with endpoint titer on monkey esophagus (ME) substrate

SS = Antibody absence (negative) or presence with endpoint titer and pattern on split skin (SS) substrate

Epi = epidermal staining pattern on split skin substrate

Dermal = dermal staining pattern on split skin substrate

Combined = combined epidermal-dermal staining pattern

BP 180 = IgG BP 180 antibody level (Units/mL) by ELISA

BP 230 = IgG BP 230 antibody level (Units/mL) by ELISA

Coll VII = IgG Collagen VII antibody level (Units/mL) by ELISA

Neg = Negative

NA = Not Assayed

COMMENTS

General

Detection of IgA antibodies to epithelial basement membrane zone is highly specific for linear IgA bullous dermatosis and is present in up to 80 percent of patients with linear IgA disease. Detection of and levels of diagnostic serum antibodies may fluctuate over time with disease expression; recommend consideration for monitoring antibody profiles and levels for persistent or progressive disease activity.

TESTING METHODS

Indirect Immunofluorescence

Basement Membrane Zone IgA Antibodies

The patient's serum is progressively diluted beginning at 1:5 in two-fold dilutions, layered on sections of monkey esophagus substrate and human skin split at the basement membrane zone substrate, and stained with fluorescein-conjugated anti-IgA using Analyte Specific Reagents (ASRs). Three screening dilutions of serum are tested and, when positive, the serum is further diluted in two-fold reductions to the limiting dilution of antibody detection or to a maximum dilution of 1:40,960. These tests were developed and their performance characteristics

H - high L - low * - abnormal C - critical

determined by the Immunodermatology Laboratory at the University of Utah. They have not been cleared or approved by the U.S. Food and Drug Administration. ASRs are used in many laboratory tests necessary for standard medical care and generally do not require FDA approval. These tests should not be regarded as investigational or for research only. [Immunofluorescence studies, one antibody on two substrates]

Immunodermatologist
Electronically signed 5/12/2017 12:34:05PM
Performed at: ARUP - University Hospital Laboratory 50 N. Medical Drive Salt Lake City UT 84132

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Epithelial BMZ Ab, IgA	17-128-137548	5/8/2017 10:55:00 AM	5/11/2017 7:42:08 AM	5/15/2017 4:32:57 PM

END OF CHART

H - high L - low * - abnormal C - critical